Design Therapeutics IncNASDAQ:DSGN
- LAST PRICE6.0000
- TODAY'S CHANGE (%)0.0300 (0.5025%)
- Bid / Lots5.5400/ 1
- Ask / Lots6.6100/ 1
- Open / Previous Close6.1000 / 5.9700
- Day Range
- 52 Week Range
- Volume44,861
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DSGN |
|---|---|---|
| 09:32 ET | 2577 | 6.1 |
| 10:08 ET | 402 | 6.04 |
| 10:20 ET | 300 | 6.12 |
| 10:27 ET | 168 | 6.08 |
| 10:40 ET | 824 | 6.105 |
| 10:42 ET | 1200 | 6.12 |
| 10:44 ET | 100 | 6.105 |
| 10:45 ET | 736 | 6.12 |
| 10:56 ET | 200 | 6.135 |
| 10:58 ET | 378 | 6.17 |
| 11:05 ET | 100 | 6.16 |
| 11:07 ET | 100 | 6.17 |
| 11:09 ET | 100 | 6.17 |
| 11:12 ET | 2193 | 6.105 |
| 11:14 ET | 108 | 6.105 |
| 11:16 ET | 100 | 6.075 |
| 11:18 ET | 1100 | 6 |
| 11:20 ET | 700 | 5.96 |
| 11:23 ET | 813 | 5.945 |
| 11:25 ET | 200 | 5.945 |
| 11:27 ET | 100 | 5.945 |
| 11:30 ET | 1656 | 6.0089 |
| 11:38 ET | 100 | 5.98 |
| 11:39 ET | 100 | 5.98 |
| 11:41 ET | 400 | 5.98 |
| 11:45 ET | 100 | 6.005 |
| 11:50 ET | 300 | 6.02 |
| 11:52 ET | 100 | 5.98 |
| 11:54 ET | 100 | 5.98 |
| 11:56 ET | 200 | 5.98 |
| 11:59 ET | 100 | 5.98 |
| 12:01 ET | 638 | 6.005 |
| 12:03 ET | 400 | 6 |
| 12:06 ET | 800 | 6.02 |
| 12:10 ET | 400 | 6.04 |
| 12:12 ET | 100 | 6.03 |
| 12:14 ET | 1000 | 6.0212 |
| 12:15 ET | 100 | 6.02 |
| 12:19 ET | 100 | 6 |
| 12:21 ET | 100 | 6 |
| 12:24 ET | 100 | 6 |
| 12:26 ET | 100 | 6 |
| 12:28 ET | 100 | 6 |
| 12:30 ET | 100 | 6 |
| 12:32 ET | 100 | 6 |
| 12:33 ET | 920 | 5.96 |
| 12:35 ET | 100 | 5.96 |
| 12:39 ET | 100 | 5.96 |
| 12:42 ET | 100 | 5.95 |
| 12:44 ET | 409 | 5.9414 |
| 12:46 ET | 100 | 5.94 |
| 12:48 ET | 100 | 5.96 |
| 12:50 ET | 100 | 5.965 |
| 12:51 ET | 100 | 5.94 |
| 12:53 ET | 300 | 5.96 |
| 12:55 ET | 100 | 5.95 |
| 12:57 ET | 100 | 5.94 |
| 01:00 ET | 7059 | 6 |
Nov 13, 2024
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences, from 8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 7, 2024
Press Release: Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow JonesDesign Therapeutics Announces Third Quarter 2024 -2-, from 4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
4:01PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Design Therapeutics Inc | 348.2M | -7.1x | --- |
Jasper Therapeutics Inc | 348.6M | -4.8x | --- |
Kodiak Sciences Inc | 344.7M | -1.8x | --- |
Q32 Bio Inc | 327.9M | -3.6x | --- |
Northwest Biotherapeutics Inc | 324.5M | -4.5x | --- |
Neurogene Inc | 383.3M | -5.7x | --- |
Company Information
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Contact Information
- Headquarters
- 6005 Hidden Valley Road, Suite 110CARLSBAD, CA, United States 92011
- Phone
- 858-293-4900
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer
- Pratik Shah
- Chief Operating Officer
- Sean Jeffries
- Chief Medical Officer
- Jae Kim
- Lead Independent Director
- Simeon George
- Independent Director
- Heather Berger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $348.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 56.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.86 |
EPS | $-0.85 |
Book Value | $4.92 |
P/E Ratio | -7.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
